Item Details / Description

CJC-1295 with DAC 10mg

CJC-1295 with DAC is a synthetic, long-acting growth hormone-releasing hormone analogue designed to stimulate the pituitary gland to increase endogenous growth hormone secretion and downstream IGF-1 activity.

The defining feature is the DAC, or Drug Affinity Complex. This modification allows CJC-1295 to bind to circulating albumin, dramatically extending its biological exposure compared with short-acting GHRH analogues such as Modified GRF 1-29, commonly marketed as "CJC-1295 No DAC."

Its primary research areas include:

• Growth hormone secretion

• IGF-1

• Body composition

• Fat metabolism

• Muscle and tissue recovery

• Collagen and connective tissue

• Sleep-related endocrine function

• Age-related decline in GH secretion

A vial labeled "CJC-1295 with DAC 10mg" represents a total of 10 milligrams of peptide in the vial. It does not mean that 10mg is an established or appropriate single human dose.

What is CJC-1295 with DAC?

CJC-1295 is a modified analogue of growth hormone-releasing hormone, or GHRH.

Natural GHRH is produced in the hypothalamus and signals the anterior pituitary gland to release growth hormone.

The basic pathway is:

CJC-1295 with DAC

GHRH receptor

Pituitary gland

Growth hormone release

IGF-1 production

Downstream metabolic and tissue effects

CJC-1295 therefore acts upstream of growth hormone rather than supplying HGH directly.

What does DAC mean?

DAC stands for:

Drug Affinity Complex

The DAC modification is designed to allow the peptide to form a covalent bond with circulating albumin.

Albumin is one of the most abundant proteins in human blood and has a relatively long circulating lifespan.

By associating with albumin, CJC-1295 avoids the extremely rapid clearance typical of ordinary GHRH peptides.

This is the central feature that makes CJC-1295 with DAC different from the No DAC version.

Why was DAC developed?

Natural GHRH is rapidly degraded.

A peptide that disappears quickly can produce only brief receptor stimulation.

The DAC concept was designed to solve this problem:

GHRH analogue

plus

Drug Affinity Complex

Albumin binding

Reduced clearance

Prolonged biological exposure

Sustained GH and IGF-1 effects

This creates a much longer-acting GHRH analogue.

CJC-1295 with DAC versus CJC-1295 No DAC

This distinction is extremely important.

CJC-1295 with DAC:

• Long acting

• Albumin binding

• Prolonged GHRH receptor stimulation

• Sustained elevation of GH and IGF-1

• Much longer biological exposure

CJC-1295 No DAC:

• Commonly refers to Modified GRF 1-29

• Short acting

• No albumin-binding DAC

• Produces a more discrete GH secretory period

• More closely associated with pulsatile GH stimulation

They should not be treated as interchangeable compounds.

Is CJC-1295 No DAC really the same compound?

Not exactly.

The term "CJC-1295 No DAC" became common in the research-peptide marketplace.

However, the compound usually sold under that name is Modified GRF 1-29.

True CJC-1295 was specifically developed with the Drug Affinity Complex.

Therefore:

CJC-1295 with DAC = true long-acting CJC-1295 concept.

"CJC-1295 No DAC" = commercial terminology generally referring to Mod GRF 1-29.

How does CJC-1295 with DAC work?

CJC-1295 binds to GHRH receptors on pituitary somatotroph cells.

This stimulates the synthesis and release of growth hormone.

The resulting GH can then act directly on tissues and stimulate production of IGF-1.

The simplified pathway is:

CJC-1295

GHRH receptor activation

Pituitary GH secretion

Increased circulating GH

Increased IGF-1

Metabolic and tissue effects

What is growth hormone?

Growth hormone is a peptide hormone produced by the anterior pituitary.

GH participates in:

• Growth

• Protein metabolism

• Fat metabolism

• Bone remodeling

• Connective-tissue biology

• Collagen production

• Muscle maintenance

• Glucose regulation

• IGF-1 production

Growth hormone is naturally released in pulses.

What is IGF-1?

IGF-1 stands for:

Insulin-Like Growth Factor 1

Growth hormone stimulates IGF-1 production, particularly in the liver.

IGF-1 participates in:

• Cellular growth

• Protein synthesis

• Muscle biology

• Bone metabolism

• Tissue repair

• Connective-tissue function

IGF-1 is therefore an important downstream marker when studying long-acting GHRH analogues.

Does CJC-1295 with DAC contain HGH?

No.

CJC-1295 does not contain human growth hormone.

It stimulates the pituitary gland to produce and release endogenous GH.

This makes it fundamentally different from pharmaceutical HGH.

CJC-1295 with DAC versus HGH

HGH:

• Is growth hormone itself

• Directly introduces exogenous GH

• Does not require pituitary stimulation

CJC-1295 with DAC:

• Is a GHRH analogue

• Stimulates endogenous GH secretion

• Requires a responsive pituitary

• Works upstream of GH

• Preserves some physiological endocrine feedback

CJC-1295 should therefore not simply be called "injectable HGH."

CJC-1295 with DAC and growth hormone pulsatility

Natural GH secretion is pulsatile.

GH levels rise dramatically during secretory pulses and then fall.

Important triggers include:

• Deep sleep

• Exercise

• Fasting

• GHRH

• Ghrelin-related signaling

CJC-1295 with DAC creates prolonged GHRH stimulation, but it does not necessarily produce completely flat, constant GH secretion.

The body's existing:

• GHRH

• Somatostatin

• Ghrelin

• Feedback mechanisms

continue to influence GH release.

CJC-1295 with DAC and IGF-1 elevation

One of the defining findings from human CJC-1295 research was prolonged elevation of IGF-1 following administration.

This demonstrates that its long duration is biologically meaningful.

A brief peptide exposure can therefore produce endocrine changes lasting substantially longer than short-acting GHRH analogues.

How long acting is CJC-1295 with DAC?

CJC-1295 with DAC was specifically designed for prolonged activity.

Its effective half-life is measured in days rather than minutes.

This contrasts sharply with short-acting Modified GRF 1-29.

The albumin-binding mechanism is responsible for much of this difference.

Why does albumin binding matter?

Small peptides are normally vulnerable to:

• Enzymatic degradation

• Renal clearance

• Rapid removal from circulation

Albumin is large and circulates for a long time.

Attaching the peptide to albumin effectively gives the peptide access to a much longer-lived circulating carrier.

This can dramatically alter pharmacokinetics.

CJC-1295 with DAC and muscle growth

CJC-1295 is not a direct anabolic steroid.

Potential muscle effects would occur indirectly through:

• GH

• IGF-1

• Protein metabolism

• Recovery

• Tissue remodeling

GH and IGF-1 clearly participate in muscle biology.

However, this does not mean CJC-1295 produces steroid-like muscle growth.

Controlled evidence for substantial muscle hypertrophy in healthy bodybuilders is lacking.

CJC-1295 with DAC and bodybuilding

The bodybuilding interest typically involves:

• Increased GH

• Increased IGF-1

• Recovery

• Fat metabolism

• Sleep

• Connective tissue

• Body composition

However, increased GH or IGF-1 laboratory values do not automatically translate into dramatic improvements in muscle mass or strength.

CJC-1295 with DAC and strength

There is insufficient evidence that CJC-1295 significantly increases maximal strength in healthy trained individuals.

Strength depends heavily on:

• Muscle mass

• Neural adaptation

• Training

• Technique

• Androgen signaling

GH is not equivalent to testosterone.

CJC-1295 with DAC and fat loss

Growth hormone can stimulate lipolysis.

Lipolysis is the breakdown of stored triglycerides into:

• Free fatty acids

• Glycerol

These fatty acids can then become available for energy.

This provides a legitimate biological basis for interest in GH-related compounds and body composition.

However, CJC-1295 is not an approved weight-loss medication.

Does CJC-1295 with DAC directly burn fat?

Not in the simplistic sense sometimes presented in marketing.

Its potential effects are mediated through the GH axis.

The theoretical pathway is:

CJC-1295

Increased GH signaling

Increased lipolytic signaling

Greater fatty-acid mobilization

Potential body-composition effects

Actual fat loss still depends on overall energy balance and numerous physiological factors.

Does CJC-1295 suppress appetite?

No significant appetite-suppressing mechanism has been established.

It does not work like:

• Cagrilintide

• Semaglutide

• Tirzepatide

Those compounds primarily influence appetite and metabolic signaling.

CJC-1295 primarily influences the GH axis.

CJC-1295 with DAC and visceral fat

Growth hormone can influence visceral adipose tissue.

However, CJC-1295 does not have the same clinical evidence for visceral-fat reduction as Tesamorelin has for its specific approved population.

CJC-1295 with DAC versus Tesamorelin

Both activate the GHRH receptor.

CJC-1295 with DAC:

• Long-acting GHRH analogue

• Albumin-binding DAC

• Experimental

• Prolonged GH and IGF-1 effects

Tesamorelin:

• Modified GHRH analogue

• Pharmaceutical product exists

• Substantial controlled human research

• Approved for reducing excess abdominal visceral fat in adults with HIV-associated lipodystrophy

Tesamorelin has a clearly established therapeutic indication.

CJC-1295 does not.

CJC-1295 with DAC versus Sermorelin

Sermorelin:

• GHRH 1-29

• Short acting

• Stimulates endogenous GH

CJC-1295 with DAC:

• Modified GHRH analogue

• Contains DAC

• Binds albumin

• Dramatically longer acting

• Produces prolonged GH and IGF-1 stimulation

Their pharmacokinetics are therefore very different.

CJC-1295 with DAC versus Ipamorelin

CJC-1295:

Activates the GHRH receptor.

Ipamorelin:

Activates the ghrelin receptor, GHS-R1a.

Both can stimulate pituitary GH release through different signaling pathways.

Why are CJC-1295 and Ipamorelin discussed together?

The theoretical rationale is complementary receptor activation.

CJC-1295:

GHRH receptor signaling.

Ipamorelin:

Ghrelin receptor signaling.

Both pathways converge on:

Pituitary GH release.

This creates the potential for enhanced GH secretion.

However, popular "CJC plus Ipamorelin" protocols are not FDA-established treatment regimens.

DAC versus No DAC when combined with Ipamorelin

This is an important conceptual difference.

With No DAC:

Short GHRH activity can overlap with the short GH-secretagogue signal from Ipamorelin.

With DAC:

The GHRH analogue remains active for a prolonged period, while Ipamorelin remains comparatively short acting.

Therefore, the endocrine profiles are not equivalent.

CJC-1295 with DAC and recovery

Growth hormone and IGF-1 participate in:

• Protein turnover

• Collagen synthesis

• Connective-tissue metabolism

• Bone remodeling

• Cellular repair

This creates biological interest in recovery.

However, CJC-1295 is not an approved treatment for athletic injuries.

CJC-1295 with DAC and tendons

Tendons contain large amounts of collagen.

GH and IGF-1 can influence collagen synthesis.

This makes GH-axis compounds interesting for connective-tissue research.

However, there is no evidence that CJC-1295 reliably reconnects or regenerates a torn human tendon.

CJC-1295 with DAC and ligaments

The same applies to ligaments.

Potential collagen effects should not be interpreted as proof of ligament regeneration.

Severe structural injuries still require appropriate diagnosis and treatment.

CJC-1295 with DAC and cartilage

GH and IGF-1 participate in cartilage biology.

However, CJC-1295 is not an established cartilage-regeneration treatment.

Claims that it "regrows joints" are not supported.

CJC-1295 with DAC and bone

The GH/IGF-1 axis influences:

• Osteoblasts

• Bone remodeling

• Bone formation

• Skeletal maintenance

However, CJC-1295 is not an approved osteoporosis treatment.

CJC-1295 with DAC and collagen

Collagen is one of the more biologically plausible areas of interest for GH-axis compounds.

Collagen is found throughout:

• Skin

• Tendons

• Ligaments

• Cartilage

• Bone

• Connective tissue

GH and IGF-1 signaling can influence collagen turnover and synthesis.

CJC-1295 with DAC and sleep

Natural GH secretion is strongly associated with slow-wave sleep.

One of the largest daily GH pulses commonly occurs during deep sleep.

This is why GH-related compounds are frequently discussed alongside:

• Sleep quality

• Recovery

• Restfulness

However, CJC-1295 is not a sedative or established insomnia treatment.

CJC-1295 with DAC and anti-aging

GH secretion generally declines with age.

This age-related decline helped drive interest in GHRH analogues.

Potential areas of interest include:

• Body composition

• Recovery

• Skin

• Energy

• Sleep

• Bone

• Muscle maintenance

However, increasing GH or IGF-1 does not mean biological aging has been reversed.

There is no evidence that CJC-1295 extends human lifespan.

More GH is not necessarily better

This is particularly important with a long-acting compound.

Growth hormone is beneficial within normal physiological ranges.

Chronic excessive GH signaling can produce significant problems.

Acromegaly demonstrates the consequences of sustained pathological GH excess.

These can include:

• Insulin resistance

• Soft-tissue growth

• Joint problems

• Cardiovascular disease

• Sleep apnea

• Organ enlargement

CJC-1295 exposure is not equivalent to acromegaly, but the disease illustrates why continuously maximizing GH is not a desirable goal.

CJC-1295 with DAC and glucose

Growth hormone can oppose some of insulin's actions.

Excessive GH signaling can therefore:

• Reduce insulin sensitivity

• Increase blood glucose

• Increase insulin requirements

Glucose metabolism is an important consideration with prolonged GH stimulation.

CJC-1295 with DAC and insulin resistance

Chronically elevated GH can promote insulin resistance.

This means a compound producing sustained GH and IGF-1 elevation may have a different metabolic risk profile from a very short GH pulse.

The long duration of the DAC version makes this especially relevant.

CJC-1295 with DAC and water retention

GH-related signaling can contribute to fluid retention.

Potential effects include:

• Puffy appearance

• Swelling

• Increased extracellular water

• Hand or foot swelling

Scale weight gained from fluid should not be confused with new muscle tissue.

CJC-1295 with DAC and carpal tunnel symptoms

GH-related fluid and soft-tissue effects can contribute to:

• Hand tingling

• Numbness

• Swelling

• Carpal-tunnel-like symptoms

These effects are well recognized with significant GH exposure.

CJC-1295 with DAC and blood pressure

Fluid retention and metabolic changes can potentially influence cardiovascular physiology.

Long-term cardiovascular safety of CJC-1295 use in healthy performance or anti-aging populations has not been established.

CJC-1295 with DAC and heart health

GH and IGF-1 have complex cardiovascular effects.

Normal signaling is physiologically important.

Chronic excess is not necessarily beneficial.

CJC-1295 should therefore not be described as a heart-health supplement.

CJC-1295 with DAC and skin

GH and IGF-1 participate in:

• Collagen production

• Connective-tissue turnover

• Skin thickness

• Cellular growth

This creates theoretical interest in skin quality.

However, CJC-1295 is not an established anti-wrinkle or dermatological treatment.

CJC-1295 with DAC and hair

There is insufficient evidence that CJC-1295 reliably increases scalp hair growth.

Common pattern hair loss is strongly influenced by genetics and androgen signaling.

Increasing GH does not automatically reverse it.

CJC-1295 with DAC and energy

Some people associate GH-related therapies with improved:

• Energy

• Recovery

• Well-being

Others can experience:

• Fatigue

• Water retention

• Headaches

• Metabolic changes

CJC-1295 is not a stimulant.

CJC-1295 with DAC and athletic performance

Theoretical areas of interest include:

• Recovery

• Body composition

• Connective tissue

• Sleep

• GH signaling

There is insufficient controlled evidence showing that CJC-1295 reliably increases:

• Strength

• Speed

• Endurance

• Power

• Competitive athletic performance

in healthy athletes.

CJC-1295 with DAC and testosterone

CJC-1295 does not primarily stimulate the reproductive hormone axis.

It is not designed to directly increase:

• GnRH

• LH

• FSH

• Testosterone

Does CJC-1295 suppress testosterone?

It is not known to suppress endogenous testosterone in the manner of anabolic steroids.

Does CJC-1295 require PCT?

Traditional steroid-style post-cycle therapy is not generally associated with CJC-1295.

It does not primarily suppress the hypothalamic-pituitary-gonadal axis.

CJC-1295 with DAC and natural GH production

The GH axis is regulated through feedback.

As GH and IGF-1 increase, the body can alter:

• GHRH secretion

• Somatostatin

• Pituitary responsiveness

Therefore, prolonged pharmacological stimulation should not be described as completely independent of natural endocrine regulation.

What is somatostatin?

Somatostatin is one of the body's primary inhibitors of GH release.

GH secretion depends partly on the balance between:

GHRH = stimulates GH.

Ghrelin-related signaling = stimulates GH.

Somatostatin = inhibits GH.

CJC-1295 increases one side of this regulatory system rather than eliminating the system entirely.

CJC-1295 with DAC and BPC-157

CJC-1295:

• GHRH receptor

• Growth hormone

• IGF-1

BPC-157:

• Experimental tissue-protection pathways

• Fibroblast migration

• Angiogenesis

• Gastrointestinal and connective-tissue research

They have completely different primary mechanisms.

CJC-1295 with DAC and TB-500

TB-500-related research focuses on:

• Actin

• Cell migration

• Angiogenesis

• Tissue repair

CJC-1295 works through endocrine GH signaling.

They should not be considered interchangeable.

CJC-1295 with DAC and AOD-9604

AOD-9604:

• HGH-derived fragment

• Primarily metabolic and fat research

• Does not primarily increase GH

CJC-1295 with DAC:

• GHRH analogue

• Stimulates endogenous GH

• Can increase IGF-1

Their mechanisms are fundamentally different.

CJC-1295 with DAC 10mg vial

A vial labeled:

"CJC-1295 with DAC 10mg"

means the supplier represents the vial as containing a total of 10 milligrams of CJC-1295.

The 10mg represents total vial content.

It should not be interpreted as an established single administration amount.

There is no FDA-approved CJC-1295 with DAC regimen for bodybuilding, anti-aging, fat loss, recovery, or general GH optimization.

Injectable CJC-1295 with DAC

Research suppliers commonly provide CJC-1295 as lyophilized powder.

An injectable-style vial does not establish that the product is an approved injectable medication.

Quality considerations include:

• Correct peptide identity

• Correct DAC modification

• Concentration

• Chemical purity

• Sterility

• Endotoxins

• Stability

• Manufacturing consistency

Half-life

The defining pharmacokinetic feature of CJC-1295 with DAC is its long duration.

Unlike Mod GRF 1-29, which is short acting, CJC-1295 with DAC can remain biologically active for days because of albumin binding.

This can produce prolonged changes in GH and IGF-1 rather than a brief isolated effect.

Duration versus No DAC

The difference can be summarized as:

No DAC:

Short exposure.

DAC:

Multi-day exposure.

This is why accidentally confusing the two products is potentially significant.

They should not be treated as though the only difference is the wording on the label.

Possible side effects

Potential adverse effects associated with CJC-1295 and increased GH/IGF-1 signaling can include:

• Injection-site reactions

• Flushing

• Headache

• Dizziness

• Fatigue

• Nausea

• Water retention

• Swelling

• Tingling or numbness

• Carpal-tunnel-like symptoms

• Joint discomfort

• Changes in blood glucose

• Reduced insulin sensitivity

Long duration can matter because adverse endocrine effects may not disappear as rapidly as those from a short-acting peptide.

Long-term safety

Long-term use in healthy individuals for bodybuilding, anti-aging, or general performance enhancement has not been adequately established.

Important concerns include:

• Persistent IGF-1 elevation

• Insulin resistance

• Glucose intolerance

• Fluid retention

• Soft-tissue growth

• Cardiovascular effects

• Sleep apnea

• Effects on abnormal cell growth

CJC-1295 with DAC and cancer

Growth hormone and IGF-1 participate in cellular growth and survival.

Therefore, manipulating this pathway can be clinically relevant in people with existing tumors or abnormal cellular growth.

This does not mean CJC-1295 has been proven to cause cancer.

It does mean claims that prolonged GH and IGF-1 stimulation are universally harmless would be inappropriate.

Product purity

Research peptide quality can vary considerably.

Potential issues include:

• Incorrect peptide

• Incorrect sequence

• Missing or incorrect DAC modification

• Incorrect vial quantity

• Degradation

• Aggregation

• Chemical impurities

• Endotoxins

• Bacterial contamination

• Poor sterility

Correctly distinguishing DAC from No DAC is especially important.

What does 99 percent purity mean?

HPLC can help evaluate chemical purity.

Mass spectrometry can help verify molecular identity.

However, 99 percent purity does not automatically establish:

• Sterility

• Endotoxin levels

• Exact vial quantity

• Correct DAC modification

• Pharmaceutical manufacturing quality

• Human safety

These require separate testing.

What does Research Use Only mean?

Research Use Only, or RUO, means a product is marketed for laboratory or analytical research rather than as an approved medication for human treatment.

An RUO CJC-1295 with DAC vial should not be treated as approved HGH therapy.

Is CJC-1295 with DAC FDA approved?

CJC-1295 with DAC is not FDA approved for:

• Growth hormone optimization

• Bodybuilding

• Muscle growth

• Fat loss

• Anti-aging

• Athletic performance

• Recovery

• Sleep enhancement

• Injury healing

• General wellness

There is no FDA-approved human dosing protocol for CJC-1295 with DAC.

How strong is the evidence?

GHRH receptor biology:

Strong.

GHRH stimulation of growth hormone:

Strong.

CJC-1295 increasing GH:

Supported by human research.

CJC-1295 increasing IGF-1:

Supported by human research.

Long-acting albumin-binding pharmacology:

Supported.

GH effects on lipolysis:

Strong.

GH and IGF-1 involvement in connective tissue:

Strong.

CJC-1295 for bodybuilding:

Not established.

Major muscle growth:

Not established.

Obesity treatment:

Not established.

Athletic performance:

Not established.

Injury healing:

Not established.

Anti-aging:

Not established.

Lifespan extension:

Not established.

Long-term use in healthy individuals:

Insufficiently characterized.

The biggest potential advantage

The defining advantage of CJC-1295 with DAC is its pharmacokinetic design.

The basic concept is:

CJC-1295

DAC modification

Albumin binding

Extended circulation

Prolonged GHRH receptor activity

Sustained endogenous GH secretion

Prolonged IGF-1 elevation

This allows a short peptide signal to produce endocrine effects lasting for days rather than minutes.

The biggest limitation

The same feature that makes CJC-1295 with DAC interesting is also one of its biggest limitations.

Prolonged stimulation means prolonged exposure.

With No DAC, the research concept emphasizes relatively short GH stimulation.

With DAC, GH and particularly IGF-1 can remain elevated for considerably longer periods.

That makes concerns involving:

• Glucose metabolism

• Insulin sensitivity

• Water retention

• Soft-tissue effects

• Excessive IGF-1

• Abnormal cell growth

more relevant.

Furthermore, demonstrating increased GH and IGF-1 does not prove meaningful bodybuilding, fat-loss, recovery, or anti-aging benefits.

Bottom line

CJC-1295 with DAC is an experimental long-acting GHRH analogue designed to stimulate endogenous growth hormone secretion and increase downstream IGF-1.

Its defining characteristic is the Drug Affinity Complex, which allows albumin binding and dramatically extends biological exposure.

Its primary research areas include:

• Growth hormone

• IGF-1

• Body composition

• Fat metabolism

• Recovery

• Connective tissue

• Collagen

• Sleep-related endocrine function

• Age-related GH decline

"CJC-1295 with DAC 10mg" describes the represented total amount of peptide contained in a vial. It should not be interpreted as a recommended 10mg dose.

The most accurate description is:

CJC-1295 with DAC is a long-acting experimental GHRH analogue with human evidence demonstrating prolonged increases in growth hormone and IGF-1. Its albumin-binding DAC modification makes it fundamentally different from the short-acting compound commonly sold as CJC-1295 No DAC. Although its endocrine mechanism is well supported, claims involving substantial muscle growth, dramatic fat loss, accelerated injury healing, athletic enhancement, or anti-aging go beyond the available clinical evidence, and the long-term safety of sustained GH and IGF-1 stimulation in healthy individuals remains insufficiently established.